Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wenwu He

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
The Oncologist|March 19, 2022
Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell CarcinomaWenwu He, Xuefeng Leng, Tianqin Mao, et al.
Nature Communications|August 20, 2024
Toripalimab plus chemotherapy and radiotherapy for treatment-naive advanced esophageal squamous cell carcinoma: a single-arm phase 2 trialLei Wu, Baisen Li, Gang Wan, et al.
Frontiers in Immunology|January 5, 2024
Peripheral T lymphocyte and immunocyte subset dynamics: markers of neoadjuvant therapy outcomes in esophageal squamous cell carcinomaXin Nie, Shuya He, Xinming Nie, et al.
Annals of Surgery|December 20, 2019
Prognostic Impact of Postoperative Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus: From the Results of NEOCRTEC5010, a Randomized Multicenter StudyXuefeng Leng, Wenwu He, Hong Yang, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
The Oncologist|March 19, 2022
Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell CarcinomaWenwu He, Xuefeng Leng, Tianqin Mao, et al.
Nature Communications|August 20, 2024
Toripalimab plus chemotherapy and radiotherapy for treatment-naive advanced esophageal squamous cell carcinoma: a single-arm phase 2 trialLei Wu, Baisen Li, Gang Wan, et al.
Frontiers in Immunology|January 5, 2024
Peripheral T lymphocyte and immunocyte subset dynamics: markers of neoadjuvant therapy outcomes in esophageal squamous cell carcinomaXin Nie, Shuya He, Xinming Nie, et al.
Annals of Surgery|December 20, 2019
Prognostic Impact of Postoperative Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus: From the Results of NEOCRTEC5010, a Randomized Multicenter StudyXuefeng Leng, Wenwu He, Hong Yang, et al.
Pageof 7